| Outcome Measures: |
Primary: changes in Hamilton Depression Rating Scale (HDRS), The HDRS will be scored by face-to-face interview., 6 months after the treatment | Secondary: changes in Mini-mental state examination (MMSE) score, MMSE questionnaire will be checked by careful interview and self-reported., 6 months after the treatment|glucometabolic parameters, fasting glucose (mg/dL), 6 months after the treatment|glucometabolic parameters, postprandial 2h glucose (mg/dL), 6 months after the treatment|glucometabolic parameters, fasting insulin (uIU/mL), 6 months after the treatment|glucometabolic parameters, homeostasis model assessment for insulin resistance (mg/dL•uIU/mL), 6 months after the treatment|glucometabolic parameters, aspartate aminotransferase (IU/L), 6 months after the treatment|glucometabolic parameters, alanine aminotransferase (IU/L), 6 months after the treatment|glucometabolic parameters, glycated hemoglobin (%), 6 months after the treatment|glucometabolic parameters, glycoalbumin (%), 6 months after the treatment|glucometabolic parameters, triglyceride (mg/dL), 6 months after the treatment|glucometabolic parameters, low-density lipoprotein (mg/dL), 6 months after the treatment|glucometabolic parameters, high-density lipoprotein (mg/dL), 6 months after the treatment
|
| Locations: |
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, 03722, Korea, Republic of
|
